Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02459080 · ClinicalTrials.gov registry record · Phase 3
Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)
A Phase 3 study, sponsored by Mylan.
- Completed
- Registry status
- Phase 3
- Development phase
- 619
- Enrollment target
NCT02459080 is a Phase 3 study that has completed, run by Mylan. The registered enrollment target is 619 participants.
The verdict
NCT02459080, a Phase 3 study, has completed, sponsored by Mylan.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 619 participants
- Enrollment target
Study Summary
The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
Interventions
- DRUG Placebo
- DRUG TD-4208
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 619 participants |
| Start Date | 2015-09 |
| Est. Completion | 2016-09 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02459080
The ClinicalTrials.gov registry entry for NCT02459080 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 619 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Mylan, which has 22 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02459080 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02459080 about?
NCT02459080 is a clinical study titled "Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD)". The purpose of this study is to measure the effectiveness and safety of TD 4208, an investigational drug being developed to treat people with moderate to very severe COPD, compared to placebo, a treatment without activity.
What is the current status of trial NCT02459080?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 619 participants. The study started on 2015-09. Estimated completion is 2016-09.
What interventions are being tested in trial NCT02459080?
The interventions under investigation include: Placebo (DRUG), TD-4208 (DRUG).
Who is sponsoring clinical trial NCT02459080?
This trial is sponsored by Mylan, which has 22 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.